Daniela Bota, MD of UC Irvine Health discusses the results of nivolumab versus nivolumab plus ipilimumab in patients with Melanoma at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.
Abstract 9508: A Randomized Phase II Study of Nivolumab or Nivolumab Combined with Ipilimumab in Patients (pts) with Melanoma Brain Metastases (mets): The Anti-PD1 Brain Collaboration (ABC)
Advertisement